Sugi Predict

Sugi Predict / Compounds / SCHEMBL646664

SCHEMBL646664

SCHEMBL646664

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C(N)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 5/20 1.00
▸ POLB P06746 1/20 0.82
▸ ADORA1 P30542 2/20 0.82
▸ DPP4 P27487 1/20 0.82
▸ MEN1 O00255 1/20 0.82
▸ SLC28A1 O00337 1/20 0.82
▸ MAP3K7 O43318 1/20 0.82
▸ SLC28A2 O43868 1/20 0.82
▸ GAPDH P04406 1/20 0.82
▸ MAPK1 P28482 1/20 0.82
▸ ADORA2A P29274 1/20 0.82
▸ ADORA2B P29275 1/20 0.82
▸ STAT6 P42226 1/20 0.82
▸ PI4KA P42356 1/20 0.82
▸ KMT2A Q03164 1/20 0.82
▸ SMN1; SMN2 Q16637 1/20 0.82
▸ PI4K2B Q8TCG2 1/20 0.82
▸ DOT1L Q8TEK3 1/20 0.82
▸ SLC29A1 Q99808 1/20 0.82
▸ PI4K2A Q9BTU6 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30612749 1.00 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL14263529 1.00 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL646666 1.00 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL646665 1.00 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL14565267 1.00 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
Phosphoric Acid SCHEMBL6763084 0.94 ADORA3 (0.89) ADORA3POLBADORA1DPP4MEN1
Phosphoric Acid SCHEMBL6763953 0.94 ADORA3 (0.89) ADORA3POLBADORA1DPP4MEN1
SCHEMBL14429033 0.91 ADORA3 (0.87) ADORA3POLBADORA1DPP4MEN1
SCHEMBL7153060 0.90 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL598130 0.90 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3296312-B1 SYNTHESIS OF PROTECTED 3'-AMINO 5'-PHOSPHORAMIDITE NUCLEOSIDE MONOMERS GERON CORP (US) 2021-03-17 — — EP claimed
EP-1778711-B1 SYNTHESIS OF PROTECTED 3'-AMINO NUCLEOSIDE MONOMERS GERON CORP (US) 2017-08-16 — — EP claimed
EP-2360166-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase Merck Sharp & Dohme Corp. (US) 2011-08-24 — — EP claimed
US-20060024687-A1 In vitro evolution of nucleic acids and encoded polypeptide WILLIAMS RICHARD B 2006-02-02 — — US claimed
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase MERCK SHARP & DOHME LLC 2004-06-10 — — US claimed
US-20040038273-A1 Bifunctional tRNA for in vitro selection WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2004-02-26 — — US claimed
US-20030022213-A1 Method for producing diverse libraries of encoded polypeptides WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2003-01-30 — — US claimed
US-6440695-B1 GENETIC ENGINEERING WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2002-08-27 — — US claimed
US-20020031762-A1 METHOD FOR PRODUCING DIVERSE LIBRARIES OF ENCODED POLYPEPTIDES WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2002-03-14 — — US claimed
US-12173368-B2 Compositions and analysis of dephosphorylated oligoribonucleotides NEW ENGLAND BIOLABS, INC. (US) 2024-12-24 — — US disclosed
US-20240301485-A1 Compositions and Analysis of Dephosphorylated Oligoribonucleotides NEW ENGLAND BIOLABS, INC. (US) 2024-09-12 — — US disclosed
US-12060384-B2 Synthesis of 1,2,5-tri-o-benzoyl-3-dibenzylamino-3-deoxyribose as intermediate for producing 3′-amino-3′-deoxyadenosine and 3′-amino-3′-deoxyguanosine and the protected derivatives thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
WO-2023197015-A1 COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES NEW ENGLAND BIOLABS, INC. (US) 2023-10-12 — — WO disclosed
US-20230287489-A1 Compositions and Analysis of Dephosphorylated Oligoribonucleotides NEW ENGLAND BIOLABS, INC. (US) 2023-09-14 — — US disclosed
EP-0420872-A4 THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES — 1992-10-21 — — EP disclosed
WO-1992012164-A1 MULTIPLY CONNECTED, THREE-DIMENSIONAL NUCLEIC ACID STRUCTURES NEW YORK UNIVERSITY (US) 1992-07-23 — — WO disclosed
EP-0420872-A1 THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES. UNIV TEMPLE (US) 1991-04-10 — — EP disclosed
US-4900407-A Method for deoxygenation of alcohols YAMASA SHOYU KABUSHIKI KAISHA (JP) 1990-02-13 — — US disclosed
US-4859768-A Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1989-08-22 — — US disclosed
EP-0238672-A1 PROCESS FOR DEOXIDIZING ALCOHOL Yamasa Shoyu Kabushiki Kaisha (JP) 1987-09-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase NSUN2, NSUN3, POLRMT ADORA3 304/4885POLB 52/4885ADORA1 493/4885
US-12060384-B2 Synthesis of 1,2,5-tri-o-benzoyl-3-dibenzylamino-3-deoxyribose as intermediate for producing 3′-amino-3′-deoxyadenosine and 3′-amino-3′-deoxyguanosine and the protected derivatives thereof STING1, CGAS, AMPD3 ADORA3 39/4885POLB 338/4885ADORA1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.